Ask AI

CME

  AMA
1.00 Credit

Driving Progress in HNSCC: Integrating Immunotherapy and Novel Targeted Therapies Across the Disease Continuum

Optimize treatment for patients with head and neck cancers by identifying those most likely to benefit from immunotherapy, designing individualized plans based on the latest clinical data and guidelines, and integrating evidence-based strategies for managing adverse events through a certified on-demand webcast, expert-written ClinicalThought commentaries, and accompanying downloadable slides.

Share

Program Content

No activities added yet

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC.

Supporters

Supported by educational grants from Coherus BioSciences, Inc. and Merck Sharp & Dohme Corp.

Coherus BioSciences, Inc.

Merck Sharp & Dohme Corp.